US Patent 7,759,359: Trospium Extended-Release Patent Scope, Claims, Expiration, and Competitive Landscape

US Patent 7,759,359 protects specific once-daily oral trospium treatment regimens for bladder dysfunction. Its core limitations are a controlled-release formulation, lower-GI release, defined pharmacokinetic exposure, and treatment of specified overactive-bladder conditions. The patent does not broadly claim all trospium formulations or all once-daily products.

The principal commercial product associated with the patent is Sanctura XR, a 60 mg once-daily extended-release trospium chloride capsule. The patent is a method-of-treatment patent rather than a pure composition, manufacturing, or formulation patent.

What does US Patent 7,759,359 cover?

US Patent 7,759,359 covers administering a once-daily formulation containing a pharmaceutically acceptable trospium salt to treat specified bladder disorders when the formulation produces defined release and blood-concentration characteristics.

The independent claims require the following elements:

Limitation	Claims 1 and 7
Active ingredient	Pharmaceutically acceptable salt of trospium
Administration route	Oral
Dosing frequency	Once daily
Release technology	Extended release, delayed release, or both
GI-site limitation	At least part of the formulation releases trospium chloride in the lower GI tract
Pharmacokinetic ceiling	Average steady-state Cmax below 2,400 pg/mL of trospium cation
Tmax	Less than six hours
Additional exposure limitation	Claim 7 requires average steady-state blood levels not to fall below 500 pg/mL
Disease indication	Urinary frequency, urgency, nocturia, urge incontinence associated with detrusor instability, urge syndrome, or detrusor hyperreflexia

The claims are cumulative. A product or regimen must satisfy every limitation of the asserted claim to create literal infringement.

How do the independent claims differ?

Claims 1 and 7 cover similar subject matter, but claim 7 adds a lower exposure-floor requirement.

Issue	Claim 1	Claim 7
Cmax	Less than 2,400 pg/mL	Less than 2,400 pg/mL
Tmax	Less than six hours	Less than six hours
Minimum average steady-state level	Not expressly required	At least 500 pg/mL
Controlled release	Required	Required
Lower-GI release	Required	Required
Treatment indications	Same	Same

Claim 7 may be narrower in practice because a competing formulation must maintain trospium exposure above 500 pg/mL while also remaining below the 2,400 pg/mL Cmax ceiling.

The patent therefore defines a pharmacokinetic window rather than merely requiring slow release:

500 pg/mL or higher average steady-state blood levels, where applicable, but less than 2,400 pg/mL Cmax and a Tmax below six hours.

That window is important because a formulation can be extended release without falling within the claims. The release profile must produce the claimed exposure.

What formulations are protected by US Patent 7,759,359?

The patent protects formulations containing one or more controlled-release components:

An extended-release component.
A delayed-release component.
A formulation combining extended-release and delayed-release components.

Claim 5 specifically covers a mixture of delayed-release and extended-release components. Claim 6 narrows that combination to 30 mg of trospium chloride in each component.

Claim 6 and the 30 mg plus 30 mg formulation

Claim 6 requires:

30 mg of trospium chloride in the delayed-release component; and
30 mg of trospium chloride in the extended-release component.

The combined dose is 60 mg of trospium chloride. This limitation maps closely to a multipart once-daily formulation containing separate release populations. A competitor using a single 60 mg extended-release matrix, a different dose split, or a different release architecture may avoid literal infringement of claim 6 while remaining potentially relevant to broader claims 1 or 7.

Lower-GI release requirement

The lower-GI limitation is central. The claims do not merely require delayed dissolution in the stomach or small intestine. At least part of the formulation must release trospium chloride in the lower gastrointestinal tract.

This limitation creates several technical infringement questions:

Where does the formulation begin releasing active ingredient?
How is "lower GI tract" defined for the product?
Does release in the ileum qualify?
Does release in the colon qualify?
What portion of the total dose must release there?
Can in vitro dissolution data establish the location of release?
Is in vivo imaging or pharmacokinetic evidence required?

A product that releases all trospium in the stomach or proximal small intestine may dispute this element. A formulation using enteric coating, pH-dependent dissolution, colon-targeting polymers, or multiparticulate delivery may present a higher infringement risk.

What are the key dependent claims?

Claim	Subject matter
2	Trospium fluoride, chloride, bromide, or iodide
3	Trospium chloride
4	Fewer incidents of specified adverse effects than 20 mg immediate-release trospium chloride administered twice daily
5	Combination of delayed-release and extended-release components
6	30 mg trospium chloride in each DR and XR component
8	Trospium fluoride, chloride, bromide, or iodide under claim 7
9	Trospium chloride under claim 7

Claims 3 and 9 are commercially important because they focus on trospium chloride, the relevant marketed salt. Claims 2 and 8 theoretically cover other halide salts, but those salts have limited apparent commercial relevance compared with trospium chloride.

How strong are the patent claims?

The patent estate is strongest against a competing product that reproduces the same once-daily controlled-release concept and achieves substantially similar pharmacokinetics. It is weaker against products that differ materially in release site, dosing schedule, salt, or PK profile.

Strengths

The claims combine formulation and clinical-use limitations.
The Cmax and Tmax requirements can distinguish a once-daily formulation from immediate-release trospium.
Claim 7 adds a defined minimum exposure level.
The lower-GI release limitation may capture multiparticulate or enteric delivery systems designed to improve tolerability.
Claim 6 directly covers a 30 mg delayed-release plus 30 mg extended-release configuration.

Vulnerabilities

The claims depend on pharmacokinetic measurements that can vary with food, sampling schedule, assay methodology, patient population, and steady-state definition.
A competitor may design around the claimed Cmax threshold.
A formulation may avoid the lower-GI limitation by releasing primarily earlier in the GI tract.
Claim 4 requires a comparative adverse-event result, which may create evidentiary disputes over study design and statistical significance.
The patent claims treatment methods, so formulation manufacture alone may not establish direct infringement without the claimed use or an inducement theory.

The overall claim strength is best characterized as moderate. The claims are commercially relevant but technically narrow.

When does US Patent 7,759,359 lose exclusivity?

The patent issued on July 20, 2010. Public patent records identify a January 31, 2005 priority date for the trospium once-daily formulation subject matter. On that basis, the standard 20-year patent term would reach January 31, 2026, subject to any patent-term adjustment or other term calculation recorded by the USPTO.

Event	Date
Earliest reported priority date	January 31, 2005
Patent issued	July 20, 2010
Nominal 20-year term endpoint	January 31, 2026
FDA approval of Sanctura XR	2009
Relevant small-molecule regulatory exclusivity	Expired before the patent term endpoint

Patent expiration is distinct from FDA regulatory exclusivity. A patent may block a generic after FDA exclusivity ends, while a generic may enter after patent expiration unless another enforceable patent or regulatory barrier remains.

Any final freedom-to-operate conclusion must use the USPTO patent-term record and the current FDA Orange Book entry, including any recorded patent-term adjustment.

What is the Orange Book status of trospium extended-release products?

Sanctura XR was approved by the FDA as a 60 mg once-daily extended-release capsule for symptoms of overactive bladder, including urge urinary incontinence, urgency, and urinary frequency. The relevant NDA is generally identified as NDA 022402 in FDA product materials.[2]

The Orange Book analysis should distinguish:

Sanctura immediate-release tablets;
Sanctura XR extended-release capsules;
patents listed against the relevant NDA;
any later-listed formulation or method-of-use patents; and
approved abbreviated new drug applications for trospium chloride extended-release capsules.

US Patent 7,759,359 is the principal patent associated with the once-daily controlled-release trospium technology. The exact Orange Book listing and current status should be read together with any later patents covering the NDA.

The Orange Book does not itself determine infringement. It identifies patents submitted by the NDA holder under the Hatch-Waxman listing framework. A generic applicant may file a Paragraph IV certification against a listed patent, and the NDA holder may sue within 45 days to obtain the statutory stay.

What Paragraph IV challenges affect trospium extended-release products?

A Paragraph IV challenge would assert that a listed patent is invalid, unenforceable, or not infringed. For this patent, likely attack points would include:

Obviousness

A challenger could argue that once-daily trospium, delayed release, extended release, and lower-GI delivery were predictable modifications of known anticholinergic formulations. The patentee would rely on the claimed PK window, tolerability results, and the specific combination of release components to establish non-obviousness.

Indefiniteness

The terms "lower gastrointestinal tract," "average Cmax at steady state," and "average steady-state blood levels" may attract claim-construction challenges. The relevant question is whether a skilled person can determine the boundaries and measurement methods with reasonable certainty.

Written description and enablement

The claims cover multiple trospium salts and multiple controlled-release designs. A challenger could argue that the specification does not adequately support the full scope of every salt, release system, and PK profile. The patentee would need to show that the disclosure enables the claimed formulation and treatment range without undue experimentation.

Infringement by PK profile

A generic applicant may attempt to design its product outside the claimed Cmax or Tmax range. Small differences in formulation can affect exposure. A product that falls outside the claimed range under its approved labeling may still face factual disputes if real-world administration produces claimed values.

The supplied record does not establish a final judgment, settlement, or currently pending Paragraph IV case specifically involving US Patent 7,759,359. A litigation database and current PACER docket review would be required to state a complete current litigation position.

What patent litigation affects Sanctura XR?

The commercial dispute profile for Sanctura XR is driven primarily by generic entry into the trospium chloride extended-release market. Relevant litigation would likely involve:

ANDA filers seeking approval for 60 mg extended-release capsules;
Paragraph IV certifications against the listed patent;
formulation and PK comparisons;
claim construction concerning lower-GI release;
inducement based on overactive-bladder labeling; and
settlement terms governing generic launch dates.

No litigation outcome should be inferred solely from the patent’s issuance or Orange Book listing. The existence of a listed patent does not prove that a generic applicant has challenged it, and a Paragraph IV filing does not establish patent invalidity.

Are there biosimilar risks for trospium?

No. Trospium chloride is a chemically synthesized small molecule, not a biologic. The relevant competitive pathway is an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Public Health Service Act.

The principal regulatory and patent risks are:

ANDA approval;
Paragraph IV certification;
bioequivalence;
formulation equivalence;
labeling carve-outs;
patent litigation; and
settlement restrictions.

Which companies compete with trospium?

Trospium competes in the overactive-bladder and urinary-incontinence markets with antimuscarinic and beta-3 adrenergic products.

Product	Active ingredient	Release type	Competitive relevance
Sanctura	Trospium chloride	Immediate release	Twice-daily antimuscarinic
Sanctura XR	Trospium chloride	Extended release	Once-daily antimuscarinic
Ditropan XL	Oxybutynin chloride	Extended release	Broad generic competition
Detrol LA	Tolterodine tartrate	Extended release	Once-daily antimuscarinic
Vesicare	Solifenacin succinate	Once daily	Branded antimuscarinic
Enablex	Darifenacin hydrobromide	Extended release	Selective M3 antagonist
Toviaz	Fesoterodine fumarate	Extended release	Once-daily antimuscarinic
Myrbetriq	Mirabegron	Extended release	Beta-3 agonist, non-antimuscarinic

Trospium’s commercial differentiation is based on once-daily dosing, controlled exposure, and reduced peak-related anticholinergic adverse effects. Its principal clinical disadvantages are class-related dry mouth, constipation, and potential adherence issues associated with administration conditions, including fasting requirements in the product labeling.[2]

What manufacturing and intellectual-property barriers remain?

The patent’s technical barriers are concentrated in formulation development rather than active-ingredient synthesis.

A competing manufacturer may need to solve:

controlled release over the dosing interval;
protection against premature release;
release in the lower GI tract;
acceptable capsule size and dose loading;
stable trospium chloride incorporation;
food-effect control;
reproducible Cmax and Tmax;
maintenance of the minimum exposure level in claim 7; and
bioequivalence to the reference product.

The patent does not appear to claim the basic chemical synthesis of trospium chloride. A manufacturer can therefore obtain the active ingredient from a qualified source without necessarily practicing the patented formulation claims. The principal risk arises when the finished product reproduces the claimed release architecture and PK results.

What generic launch scenarios exist?

Launch after patent expiration

This is the lowest patent-risk pathway if no unexpired Orange Book patent remains and regulatory requirements are satisfied.

Paragraph IV launch

A generic applicant may challenge the patent before expiration. The applicant could launch after prevailing in litigation, obtaining dismissal, reaching a settlement, or accepting litigation risk.

Non-infringing design-around

A competitor may pursue a formulation that:

releases outside the lower GI tract;
produces a Cmax at or above the claimed threshold;
produces a Tmax of six hours or longer;
does not maintain the claim 7 minimum concentration;
uses a different dosing frequency; or
relies on a different active ingredient or therapeutic class.

Authorized or licensed entry

The patent holder or brand-rights holder may authorize entry under a settlement or license. Public patent records alone do not establish whether such an agreement exists or its permitted launch date.

How does US Patent 7,759,359 compare with other overactive-bladder patent estates?

US Patent 7,759,359 is narrower than a broad active-ingredient patent but more difficult to design around than a simple dosage claim because it combines release technology with clinical PK performance.

Patent-estate type	Typical scope	Design-around potential
Active-ingredient patent	Chemical compound or salt	Low before expiration
Composition patent	Formulation composition	Moderate
Release-profile patent	Dissolution or delivery parameters	Moderate to high
Method-of-treatment patent	Drug, dose, indication, and patient treatment	Depends on labeling and use
7,759,359 claim structure	Once-daily trospium, lower-GI release, PK limits, bladder dysfunction	Moderate, with significant testing burden

The patent is more relevant to Sanctura XR than to immediate-release trospium or competing overactive-bladder drugs.

Key Takeaways

US Patent 7,759,359 is a method-of-treatment patent covering once-daily controlled-release trospium regimens.
Claims 1 and 7 require lower-GI release and a Cmax below 2,400 pg/mL with a Tmax below six hours.
Claim 7 adds a minimum average steady-state blood level of 500 pg/mL.
Claims 5 and 6 target combined delayed-release and extended-release formulations, including a 30 mg plus 30 mg trospium chloride configuration.
Claims 3 and 9 focus on trospium chloride, the commercially relevant salt.
The reported nominal patent-term endpoint is January 31, 2026, subject to the USPTO’s official term calculation.
The patent does not create biosimilar risk because trospium is a small molecule.
Generic risk depends on Orange Book listings, Paragraph IV activity, formulation design, PK data, and any later patents.
The main technical design-around opportunities involve release location, exposure profile, dosing frequency, and formulation architecture.
The patent’s overall strength is moderate: commercially meaningful, but constrained by multiple measurable technical and pharmacokinetic limitations.

FAQs

Does US Patent 7,759,359 cover immediate-release trospium chloride?

No. The independent claims require a once-daily formulation with an extended-release or delayed-release component and lower-GI release. Twice-daily 20 mg immediate-release trospium is outside the express scope of the independent claims.

Does a 60 mg once-daily trospium product automatically infringe the patent?

No. Dose alone is insufficient. The product must also satisfy the release-site and pharmacokinetic limitations, including the claimed Cmax and Tmax requirements.

Can a generic avoid the patent by using a different trospium salt?

Potentially, but claims 2 and 8 expressly cover fluoride, chloride, bromide, and iodide salts. A different salt would need to be evaluated against the full claim language and the doctrine of equivalents.

Is the lower-GI release limitation common in generic trospium formulations?

It is a material technical limitation for this patent. A generic product using a different release location may reduce literal infringement risk, but it must still meet FDA bioequivalence and formulation requirements.

Does expiration of US Patent 7,759,359 guarantee immediate generic entry?

No. Generic entry may remain subject to other unexpired patents, regulatory requirements, litigation outcomes, settlement terms, supply qualification, and FDA approval timing.

References

United States Patent and Trademark Office. (2010). U.S. Patent No. 7,759,359, Once-daily formulations of trospium.
U.S. Food and Drug Administration. (2009). Sanctura XR (trospium chloride) extended-release capsules prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
U.S. Food and Drug Administration. (2024). Abbreviated new drug application submissions and Paragraph IV certifications.
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term calculation resources.

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	493981	⤷ Start Trial
Australia	2004289223	⤷ Start Trial
Canada	2537103	⤷ Start Trial
Germany	602004030931	⤷ Start Trial
Denmark	2210605	⤷ Start Trial
European Patent Office	1680110	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,759,359

Summary for Patent: 7,759,359